- Home
- NNY vs CHRS Comparison
NNY vs CHRS Comparison
Compare NNY & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNY
- CHRS
- Stock Information
- Founded
- NNY 1987
- CHRS 2010
- Country
- NNY United States
- CHRS United States
- Employees
- NNY N/A
- CHRS N/A
- Industry
- NNY Investment Managers
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NNY Finance
- CHRS Health Care
- Exchange
- NNY Nasdaq
- CHRS Nasdaq
- Market Cap
- NNY 155.8M
- CHRS 159.2M
- IPO Year
- NNY N/A
- CHRS 2014
- Fundamental
- Price
- NNY $8.36
- CHRS $1.35
- Analyst Decision
- NNY
- CHRS Strong Buy
- Analyst Count
- NNY 0
- CHRS 4
- Target Price
- NNY N/A
- CHRS $4.51
- AVG Volume (30 Days)
- NNY 50.9K
- CHRS 1.2M
- Earning Date
- NNY 01-01-0001
- CHRS 11-05-2025
- Dividend Yield
- NNY 4.04%
- CHRS N/A
- EPS Growth
- NNY N/A
- CHRS N/A
- EPS
- NNY N/A
- CHRS 1.55
- Revenue
- NNY N/A
- CHRS $272,209,000.00
- Revenue This Year
- NNY N/A
- CHRS N/A
- Revenue Next Year
- NNY N/A
- CHRS $109.48
- P/E Ratio
- NNY N/A
- CHRS $0.87
- Revenue Growth
- NNY N/A
- CHRS 52.33
- 52 Week Low
- NNY $7.58
- CHRS $0.66
- 52 Week High
- NNY $8.87
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- NNY 72.12
- CHRS 64.99
- Support Level
- NNY $8.24
- CHRS $1.23
- Resistance Level
- NNY $8.39
- CHRS $1.40
- Average True Range (ATR)
- NNY 0.08
- CHRS 0.08
- MACD
- NNY 0.03
- CHRS -0.00
- Stochastic Oscillator
- NNY 81.40
- CHRS 72.13
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.